Reduced menstrual blood loss by release of an antifibrinolytic agent from intrauterine contraceptive devices

Tauber, P. F.; Klöppel, A.; Goodpasture, Jessie C.; Burns, Jaime; Ludwig, H; Zaneveld, L. J. D.

doi:10.1016/0002-9378(81)90282-9

Cited by 11 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A more recent study described a mean reduction of similar magnitude (295ml reduced to 155ml) in 15 women (Andersch et al 1988). The potential of introducing antifibrinolytic medication directly into the uterine cavity by means of an intrauterine device has also been explored (Tauber et al 1981). The potential of introducing antifibrinolytic medication directly into the uterine cavity by means of an intrauterine device has also been explored (Tauber et al 1981).…”

Section: Tranexamic Acidmentioning

confidence: 99%

Risk-Benefit Assessment of Drugs Used for the Treatment of Menstrual Disorders

Higham

Shaw

1991

Drug Safety

View full text Add to dashboard Cite

This article considers the benign yet debilitating conditions of menorrhagia, dysmenorrhoea and irregular menstrual bleeding. Surprisingly little has been reported in the literature concerning these common ailments which can detract from the quality of female life during the reproduction years. Both dysmenorrhoea and menorrhagia are subjective complaints, but despite accurate means of measuring menstrual blood loss such quantification is rarely performed. This lack of diagnostic accuracy is a cause for concern, especially as both medical and surgical treatment are not without risk. The therapeutic alternatives which are commonly prescribed in an attempt to rectify such menstrual disorders are discussed. These include the nonsteroidal anti-inflammatory agents, the combined oral contraceptives, danazol, progestogens, antifibrinolytics, haemostatics, luteinising hormone releasing hormone analogues and clomiphene. The results of clinical trials which have utilised these various agents are considered in terms of both the effectiveness of treatment and its potential adverse effects.

show abstract

Section: Tranexamic Acidmentioning

confidence: 99%

Risk-Benefit Assessment of Drugs Used for the Treatment of Menstrual Disorders

Higham

Shaw

1991

Drug Safety

View full text Add to dashboard Cite

show abstract

“…Measurement of menstrual loss continues to be of clinical importance because it is related to diagnosis of menstrual-related iron deficiency anemia [1], to diagnosis and treat ment of menorrhagia [2][3][4] and to acceptabil ity of intrauterine devices [5,6], Further-more, measurement of menstrual loss is im portant in population studies where men strual patterns are related to health problems of women of reproductive age.…”

Section: Introductionmentioning

confidence: 99%

“…The concentration of extracted iron is then compared to the concentration in 1 ml of the subject's blood [6][7][8]. While these tech- niques produce good replication of results, the presence of dyes in the sanitary products and the inability to extract all iron cause val ues to be consistently low with optimal re covery being about 80% [7], In addition to producing consistently low evaluations, iron analysis methods require an existing laboratory for drawing of blood, ex traction of iron, and spectrophotomctric comparison of samples.…”

Section: Introductionmentioning

confidence: 99%

A Rapid, Noninvasive Method for Evaluation of Total Menstrual Loss

Pendergrass¹,

Scott²,

Ream³

1984

Gynecol Obstet Invest

View full text Add to dashboard Cite

Three types of packages containing enough sanitary supplies for one menstrual period were weighed and distributed to 100 subjects to determine adequacy of supplies and compliance to protocol. Returned packages were then reweighed to determine total menstrual loss. No subject used all the supplies in her package; therefore, packages contents were deemed ample. 7 subjects added their own purchased products to their packages; since added products were specified by name, weight corrections were easily made. 2 subjects lost unused supplies which were specified, and weight corrections were made accordingly. Evaporative loss from sealed and stored and frequently opened packages was measured. 100 g distilled water were added to contents inside 60 packages which were sealed and set aside 7 days. Average loss from these packages was 0.65 ± 0.57 g. 5 g water were added to 60 packages 4 times daily for 5 days (100 g total). Then packages were set aside for 2 days and weighed on day 7. Average loss from these packages was 1.25 ± 0.85 g. The combination of storage plus frequent opening resulted in an average loss of 1.90 ± 0.87 g. Thus, the direct-weight method permits recovery of 97–98% of sample.

show abstract

Treatment of increased menstrual blood loss in iud users

Toppozada

1987

Contraception

View full text Add to dashboard Cite

Reduced menstrual blood loss by release of an antifibrinolytic agent from intrauterine contraceptive devices

Cited by 11 publications

References 14 publications

Risk-Benefit Assessment of Drugs Used for the Treatment of Menstrual Disorders

Risk-Benefit Assessment of Drugs Used for the Treatment of Menstrual Disorders

A Rapid, Noninvasive Method for Evaluation of Total Menstrual Loss

Treatment of increased menstrual blood loss in iud users

Contact Info

Product

Resources

About